Gapping up
In reaction to earnings/guidance:
- HOG +8.5%, STL +1.8%, GEL +1.8% (sees Q1 net loss of $33-35 mln; sees Q1 adjusted EBITDA of $143-145 mln) KO +1.2%,
M&A news:
- KNL +30.8% (merging with Herman Miller (MLHR)), .
Other news:
- CLNE +15.6% (signed an agreement with Amazon (AMZN) to provide low and negative carbon renewable natural gas)
- GME +9.3% (George Sherman will be stepping down as Chief Executive Officer on July 31, 2021, or earlier upon the appointment of a successor), MILE +7.9% (CEO Mad Money appreance)
- MANU +7.5% (announcing participation in new Super League)
- PETQ +6.9% (Positive view on Barron's)
- AVDL +6.7% (presents new data from its pivotal REST-ON phase 3 trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting)
- XBIT +5.9% (FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer)
- MNKD +4.1% (and United Therapeutics (UTHR) reach a milestone in the development of Tyvaso DPI with New Drug Application submitted to the FDA)
- TBIO +4% (appoints Brendan Smith as CFO and announces publication of preclinical results of COVID-19 mRNA vaccine candidate MRT5500 in npj vaccines)
- KZIA +3.7% (licenses global rights to EVT801, a novel, first-in-class, clinic-ready, VEGFR3 inhibitor, from Evotec)
- CYAD +3.7% (announced the appointment of Dr. Charles Morris to the position of Chief Medical Officer)
- LIZI +3.5% (enters into in-car audio collaboration with WM Motor)
- GILT +3% (received orders of over $20 mln for support of gateways of Low Earth Orbit constellations)
- CTSO +2.8% (FDA granted conditional approval of its investigational device exemption application for the U.S. Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) randomized, controlled trial)
- SWBI +2.4% (Protesters in Oakland, California set fires to a car dealership and smashed windows)
- DADA +1.3% (achieved doubling sales during 4.15 Anniversary Shopping Festival)
- AZN +1.3% (Ontario Canada to expand use of its COVID vaccine)
- SNY +1% (European Commission approves second indication of Sarclisa for relapsed multiple myeloma ) AACQ +0.9% (Origin Materials provides the following business update ahead of its Analyst Day), .
Analyst comments:
- ZNGA +4.5% (initiated with an Outperform at BMO)
- FSLR +3.3% (upgraded to Buy from Neutral at Citigroup)
- LTHM +3% (upgraded to Outperform from In-line at Evercore ISI)
- ALB +2.3% (upgraded to Outperform from In-line at Evercore ISI)
- GLW +1.2% (upgraded to Overweight from Neutral at JP Morgan)
- TXT +1.2% (upgraded to Outperform from Neutral at Credit Suisse)
- VVV +1.1% (upgraded to Buy from Hold at Jefferies)
- BKR +1% (upgraded to Outperform from Market Perform at BMO),